Johnson & Johnson's Carvykti becomes the first FDA-approved BCMA-targeted therapy for multiple myeloma patients with prior treatment.
Johnson & Johnson's Carvykti receives FDA approval for earlier treatment of multiple myeloma patients, making it the first BCMA-targeted therapy for those who have experienced at least one prior line of therapy. Carvykti is a cell therapy that uses a patient's immune system to fight the disease. Its FDA approval now positions it ahead of Bristol Myers Squibb's CAR-T therapy, Abecma, which was approved as a third-line option.
April 08, 2024
3 Articles